Patients with advanced-stage non-small-cell lung cancer (NSCLC) harbouring ROS1 fusions (~1–2% of all patients) can derive benefit from ROS1 tyrosine-kinase inhibitors (TKIs), such as entrectinib or crizotinib. Nonetheless, acquired resistance to these agents is common, and CNS activity is often limited. Now, data from TRIDENT-1, a large-cohort phase I/II trial, demonstrate the safety and efficacy of the second-generation ROS1 TKI repotrectinib, both in TKI-naive and in TKI-pretreated patients with ROS1-fusion-positive NSCLC.

中文翻译：

---

Repotrectinib 对 ROS1 融合阳性 NSCLC 有效

携带ROS1融合的晚期非小细胞肺癌 (NSCLC) 患者（约占所有患者的 1-2%）可以从 ROS1 酪氨酸激酶抑制剂 (TKI) 中获益，例如 entrectinib 或 crizotinib。尽管如此，对这些药物的获得性耐药性很常见，并且中枢神经系统活动通常受到限制。现在，大队列 I/II 期试验 TRIDENT-1 的数据证明了第二代 ROS1 TKI repotrectinib 对于未接受过 TKI 治疗和接受过 TKI 治疗的 ROS1 融合阳性NSCLC患者的安全性和有效性。